Exchange: NASDAQ·Updated 05:50 PM EDT

INSM News

News
all
press releases
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for...
PR Newswire
More News
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Expands Community Impact During Fifth Annual Global Day of Good Insmed Expands Community Impact During Fifth Annual Global Day of GoodPR NewswireBRIDGEWATER, N.J., Sept. 16, 2026 Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout...
PR Newswire
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Zacks
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
Zacks
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake...
Yahoo! Finance: News
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of $27.58 billion.read more...
Benzinga
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Sept. 4, 2026 BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global...
PR Newswire
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 Insmed to Present Data Across Its Respiratory Portfolio, Including New...
PR Newswire
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of $26.34 billion.read more...
Benzinga

Advertisement|Remove ads.